All In Biotech

Drug Trial Radar · NCT07221734

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 632 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

632

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Apr 2027

Study completion Feb 2029

Sponsor

Lead sponsor
mAbxience Research S.L.Industry
Sponsor type
Industry
First posted
Oct 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma

Conditions

  • Advanced (Unresectable or Metastatic) Melanoma

Interventions

  • MB11 (Proposed Nivolumab Biosimilar)Drug

    During fist 12 cycles: 3 mg/kg IV infusion, over 30 minutes, Q2W. On Cycle 13 onwards: 3 mg/kg IV infusion, over 30 minutes, Q2W or 240 mg flat dose Q2W dosing

  • EU-Opdivo®Drug

    During fist 12 cycles: 3 mg/kg IV infusion, over 30 minutes, Q2W. On Cycle 13 onwards: 3 mg/kg IV infusion, over 30 minutes, Q2W or 240 mg flat dose Q2W dosing

  • US- sourced Opdivo®Drug

    During fist 12 cycles: 3 mg/kg IV infusion, over 30 minutes, Q2W. On Cycle 13 onwards: 3 mg/kg IV infusion, over 30 minutes, Q2W or 240 mg flat dose Q2W dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the Pharmacokinetic (PK) bioequivalence between MB11 and EU/ US-Opdivo.Time frame: Week 1 - Week 24
  2. To demonstrate the efficacy equivalence of MB11 and Opdivo® administered as first-line treatment in adult subjects with untreated, unresectable, or metastatic Stage III or Stage IV melanomaTime frame: Week 1 - Week 24

Locations

86 sites in 13 countries. Site status is shown where the registry gives one.

  • Site 102002

    Banja Luka, Bosnia and Herzegovina · Recruiting

  • Site 102001

    Sarajevo, Bosnia and Herzegovina · Recruiting

  • Site 102003

    Zenica, Bosnia and Herzegovina · Recruiting

  • Site 103009

    Barretos, Brazil · Recruiting

  • Site 103007

    Belo Horizonte, Brazil · Recruiting

  • Site 103008

    Belo Horizonte, Brazil · Recruiting

  • Site 103002

    Bento Gonçalves, Brazil · Recruiting

  • Site 103014

    Blumenau, Brazil · Recruiting

  • Site 103012

    Caxias do Sul, Brazil · Recruiting

  • Site 103004

    Ijuí, Brazil · Recruiting

  • Site 103013

    Jaú, Brazil · Recruiting

  • Site 103015

    Lajeado, Brazil · Recruiting

  • Site 103010

    Natal, Brazil · Recruiting

  • Site 103001

    Porto Alegre, Brazil · Recruiting

  • Site 103011

    Ribeirão Preto, Brazil · Recruiting

  • Site 103018

    Rio de Janeiro, Brazil · Recruiting

  • Site 103017

    Santa Cruz do Sul, Brazil · Recruiting

  • Site 103005

    São Caetano do Sul, Brazil · Recruiting

  • Site 103016

    São Paulo, Brazil · Recruiting

  • Site 103006

    Sorocaba, Brazil · Recruiting

  • Site 104002

    Independencia, Chile · Recruiting

  • Site 104004

    La Florida, Chile · Recruiting

  • Site 104003

    Providencia, Chile · Recruiting

  • Site 104005

    Providencia, Chile · Recruiting

  • Site 104001

    Viña del Mar, Chile · Recruiting

  • Site 105002

    Batumi, Georgia · Recruiting

  • Site 105001

    Tbilisi, Georgia · Recruiting

  • Site 105003

    Tbilisi, Georgia · Recruiting

  • Site 105004

    Tbilisi, Georgia · Recruiting

  • Site 106001

    Efkarpia, Greece · Recruiting

  • Site 107002

    Catanzaro, Italy · Recruiting

  • Site 107001

    Siena, Italy · Recruiting

  • 109003

    Arequipa, Peru · Recruiting

  • 109001

    Lima, Peru · Recruiting

  • 109002

    Lima, Peru · Recruiting

  • 109004

    Lima, Peru · Recruiting

  • 109005

    Trujillo, Peru · Recruiting

  • Site 111003

    Funchal, Portugal · Recruiting

  • Site 111001

    Lisbon, Portugal · Recruiting

  • Site 111002

    Lisbon, Portugal · Recruiting

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.